Surgery or radiotherapy for prostate cancer? What the SBRT headlines leave out

October 7, 2026 By Ashwin Sridhar

Mr Ashwin Sridhar, Consultant Urological Surgeon · October 2026

Illustration of robotic surgical equipment beside a radiotherapy machine.

When you are diagnosed with localised prostate cancer, choosing between surgery (robot-assisted radical prostatectomy, or RARP) and focused radiation like SBRT (stereotactic body radiotherapy, often known by brand names like CyberKnife) can feel overwhelming.

Headlines and short videos often reduce this complex choice to simple slogans: “The cure rates are identical,” or “Radiation protects urinary function.” Much of this discussion cites PACE-A, a clinical trial that directly compared surgery with SBRT.

Looking beneath the surface of the trial reveals significant statistical limitations. And comparing trial averages ignores a basic clinical reality: continence after surgery depends on the surgeon and the centre, whereas SBRT side effects depend largely on the treatment itself.

1. Are cure rates “basically the same”? Not so fast.

PACE-A was originally designed to test whether SBRT controlled cancer as well as surgery (freedom from biochemical failure). However, randomised trials asking men to accept a computer coin-flip between an operation and radiation are notoriously hard to recruit to.

Because recruitment was so slow, the trial was redesigned in 2017, and its primary endpoints changed from cancer control to patient-reported outcomes (daily pad use and bowel scores). [1]

Even with a revised target of 234 patients, the trial closed early after recruiting only 123 men (60 surgery, 63 SBRT). [1]

Over an 8-year median follow-up: [2]

  • Only 13 cancer recurrence events occurred across the entire trial (8 surgery, 5 SBRT).
  • The hazard ratio had an extremely wide 95% confidence interval (0.16 to 1.46, p = 0.18).

In medical statistics, failing to show a significant difference in an underpowered study with only 13 events does not prove two treatments are equivalent. PACE-A offers encouraging data for SBRT, but it cannot justify declaring the two treatments “oncologically identical”.

2. The missing data problem: nearly half the surgery group

When judging quality-of-life findings in a clinical trial, how complete the data is matters just as much as the answers themselves. In PACE-A, the headline quality-of-life conclusions rely on questionnaires patients fill in themselves (patient-reported outcome measures, or PROMs).

At the main 2-year analysis point, many of those answers were missing: [1]

  • Of the 60 men randomised to surgery, only 32 gave answers on pad use. Some never had the operation and others did not return their questionnaires, but either way nearly half the surgery group is missing.
  • Of the 63 men randomised to SBRT, 46 did.
  • For sexual function, only 28 men in the surgery group had usable before-and-after scores.

When this many participants drop out of survey reporting, attrition bias becomes a real risk. Patients struggling with severe incontinence, erectile difficulties or distress after treatment are often far less inclined to complete long health questionnaires than those who have recovered well. Drawing firm conclusions from 32 surgical patients and 46 radiation patients across an entire multi-centre trial leaves the functional data highly uncertain.

3. Continence depends on the surgeon; radiation depends on the treatment

A major talking point from PACE-A is that 50% of surgical patients reported using pads at 2 years, compared with 6.5% in the SBRT group. [1]

What the headlines leave out is that 15 of those 16 surgical patients used a single pad a day, and the trial’s own authors suggest some men may have been wearing one as a “security” measure rather than because of significant leakage. [1]

To judge this fairly, you also need to understand how surgical trials are run compared with how surgery is performed in specialist centres.

The low-volume threshold of PACE-A. PACE-A allowed surgical centres with a minimum annual caseload of just 25 prostatectomies. [1] Radical prostatectomy has one of the steepest volume-outcome learning curves in cancer surgery. Blending outcomes across mixed, lower-volume settings does not reflect what is achieved at high-volume specialist centres.

High-volume centre outcomes: real-world evidence. In dedicated, high-volume centres using advanced surgical planning, continence rates tell a very different story, even in aggressive disease.

In our study published in BJU International, we looked at 1,385 men who had robotic prostatectomy at UCLH using patient-specific surgical planning (PSSP), with MRI-guided, tailored nerve-sparing. [3]

At 12 months, using a strict definition of no pads at all:

  • 81% of men with no high-risk features who had nerve-sparing surgery were completely pad-free, and 76% of men with one high-risk feature.
  • Even among men with the most aggressive disease, meeting two or more STAMPEDE high-risk criteria (Gleason 8 to 10, cT3/T4, or PSA of 40 ng/mL or more), nerve-sparing was possible in 57%, and 73% of them were completely pad-free.
  • Preserving the nerves in these high-risk men did not compromise cancer control. Positive margin rates (21.3% vs 23.2%) and 12-month biochemical recurrence (6.7% vs 5.4%) were similar with and without nerve-sparing.

Why this distinction matters. With SBRT, delivery follows set machine and beam parameters, so the side-effect profile depends largely on the treatment itself. With robotic surgery, outcomes depend heavily on the surgeon and the technique. Choosing an experienced, high-volume robotic surgeon who tailors nerve preservation to you makes a real difference to recovery.

4. Urinary problems: leakage vs irritation and obstruction

A urinary pad measures leakage (stress incontinence). It does not measure overall urinary health. Surgery and radiation affect the urinary tract in opposite ways:

  • Radical prostatectomy alters the urinary sphincter mechanism, carrying an early risk of stress incontinence that improves over time with pelvic floor rehabilitation and expert surgical technique. But it removes the obstructing prostate, often curing existing symptoms of benign prostatic enlargement (BPH).
  • SBRT delivers high-dose radiation right next to the bladder neck and urethra. Stress leakage is rare, but SBRT frequently causes irritative symptoms: sudden urgency, burning (dysuria), passing urine often, and waking several times at night (nocturia). For men who already have urinary obstruction, radiation can make symptoms worse.

In PACE-A itself, looking across the broader urinary picture at 2 years: [1]

  • Irritative and obstructive symptoms: surgery scored significantly better than SBRT (median 100 vs 93.8, p = 0.01).
  • Overall urinary symptoms: 38% of SBRT patients had moderate or severe symptoms on the standard IPSS score, compared with 16% after surgery.
  • Overall urinary bother: when asked how much their urinary symptoms bothered them overall, 3.1% in the surgery group and 4.4% in the SBRT group reported a moderate or severe problem (p = 0.8).

Patients did not escape urinary side effects with SBRT. They experienced a different set of them.

5. Sexual function and the “no hormone therapy” caveat

PACE-A reported better sexual function scores in the SBRT group. [1] Counselling patients with these numbers needs two important caveats:

  • Even fewer questionnaires. The sexual function comparison rests on just 28 surgical patients with before-and-after scores, making these numbers exploratory at best.
  • The artificial “no hormone therapy” rule. To compare radiation and surgery alone, PACE-A did not allow androgen deprivation therapy (ADT, or hormone therapy). [1]

In routine practice, guidelines recommend short-term hormone therapy alongside radiotherapy for many men with intermediate-risk prostate cancer. In the UK, NICE advises offering six months of hormone therapy with radical radiotherapy for intermediate-risk disease and above. [4]

Surgery patients do not have hormone therapy for localised disease. Hormone therapy suppresses testosterone, causing tiredness, loss of muscle, hot flushes and severe erectile dysfunction that can take a year or more to recover. Claiming SBRT preserves potency better, without making clear that many radiotherapy patients in real life need months of hormone therapy, paints an incomplete picture.

Robotic surgery and SBRT side by side

AspectRobot-assisted radical prostatectomyPrecision SBRT
What decides the outcomeThe surgeon and the centre (experience, case volume, MRI-guided planning)The treatment itself (radiation dose distribution and tissue tolerance)
Urinary side effectsStress incontinence early on; 73% to 81% completely pad-free at 12 months at our centreBurning, frequency, urgency, waking at night; may worsen existing obstruction
Enlarged prostate and flowUsually relieves bladder outlet obstructionMay worsen existing problems passing urine
Hormone therapyNot needed for localised diseaseOften needed, around 6 months, for intermediate-risk cancer
StagingFull analysis of the whole prostate and lymph nodes, confirming exact grade and marginsIndirect, via biopsies and imaging; PSA settles slowly over months

Exploring all options: the need for definitive trials

Anyone diagnosed with localised prostate cancer should explore all their treatment options with both a urological surgeon and an oncologist. Studies like PACE-A are encouraging signs that newer radiotherapy techniques, including five-session SBRT, are promising and convenient options for localised disease.

But given the small numbers, the redesign partway through and how many questionnaires were never returned, we still lack definitive head-to-head proof. Larger, properly powered trials are still needed before concluding that cancer control and side effects are truly equivalent between surgery and SBRT. In the meantime, understanding the trade-offs of each, and how much surgical volume and technique matter, is the key to choosing the right treatment.

If you have just been diagnosed and are weighing up surgery and radiotherapy, book a consultation or call 020 3150 2282 and we will go through both properly.

Related: robotic prostatectomy · focal therapy: the honest version

References

  1. van As N, Yasar B, Griffin C, et al. Radical prostatectomy versus stereotactic radiotherapy for clinically localised prostate cancer: results of the PACE-A randomised trial. European Urology 2024;86(6):566-576. doi:10.1016/j.eururo.2024.08.030
  2. van As N, et al. Efficacy of radical prostatectomy versus SBRT for localized prostate cancer: results from the PACE-A randomised controlled trial. Late-breaking abstract, ASTRO Annual Meeting 2026.
  3. Bilé-Silva A, Rajan P, Lamb B, et al., Sridhar A, Tandogdu Z. Oncological and continence outcomes after nerve-sparing robot-assisted radical prostatectomy in selected STAMPEDE-defined high-risk prostate cancer. BJU International 2026. doi:10.1111/bju.70460
  4. National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management (NG131), recommendation 1.3.22. nice.org.uk/guidance/ng131

General information, not a substitute for advice from your own medical team.

Testimonials

Mr. G. G. / London

Five stars. Every aspect: Tremendously learned and dedicated to his chosen specialisation. He emanates a feeling of both warmth and sincerity - before, during and post op. Thank You.

Mr. J. H. / Essex

Very professional and dedicated in what he does. I wish I’d have come to this surgeon first.